ELTX Elicio Earnings per share for the last twelve months

Symbol and logo of brand Elicio Therapeutics (ELTX)

The rolling revenue per share metric for Elicio Therapeutics (ELTX) demonstrates the impact of the AMP platform's success in treating KRAS-mutated tumors, with the metric holding around -1.81. However, the absence of sales and clinical trial costs are weighing on liquidity, necessitating strict cash management and adherence to temperature controls during the transport of bioactive components to ensure treatment safety.

ELTX Elicio Therapeutics, Inc Earnings per one share for the last 12 months (02/21/2024 - 11/17/2026)

Analytical breakdowns and data insights for company Elicio Therapeutics, Inc (ELTX)

Fundamental valuation:ELTX - Elicio Therapeutics, Inc
Mass-produced product of Elicio

Net income per share over 12 months measures the actual return on each ownership stake, excluding the impact of the total issuance volume on the assessment of business efficiency. By analyzing the annual net income per share chart, an investor can observe the dynamics of capital scaling, which is critically important for Elicio Therapeutics (ELTX) when financing the development of personalized cancer vaccines for the lymphatic system.